Allogene Therapeutics, Inc. (NASDAQ:ALLO), a biotechnology company specializing in the development of allogeneic CAR T cell therapies, stands at a critical juncture in its journey to bring innovative ...

In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on Allogene Therapeutics (ALLO – Research ...

Baird says Allogene Therapeutics’s (ALLO) cemacabtagene ansegedleucel data update is positive. The firm is “quite encouraged” by the update, ...

Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in ...

The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...

Allogene Therapeutics Inc . (NASDAQ:ALLO) stock has tumbled to $1.73, hitting new lows as the biotechnology firm faces a tough market environment. With a market capitalization of $377 million, the ...

Shares of US clinical-stage biotech Allogene Therapeutics rocketed 41% to $1.99 on Friday, as it announced the publication of ...

Any available webcasts will be posted to the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following a live webcast, a replay will be available on ...

Allogene Therapeutics reports promising results for cema-cel, an allogeneic CAR T therapy for relapsed/refractory large B-cell lymphoma. Allogene Therapeutics has published promising results from ...

USA News GroupNews Commentary – Despite optimism coming from the launch of Project Stargate (a $500 billion investment in AI ...